Your browser is no longer supported. Please, upgrade your browser.
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E1134.39 EPS (ttm)0.06 Insider Own0.09% Shs Outstand1.26B Perf Week-2.53%
Market Cap81.30B Forward P/E9.50 EPS next Y6.81 Insider Trans-1.13% Shs Float1.25B Perf Month2.49%
Income123.00M PEG348.18 EPS next Q2.03 Inst Own79.40% Short Float1.87% Perf Quarter2.57%
Sales24.69B P/S3.29 EPS this Y-97.70% Inst Trans-0.36% Short Ratio2.85 Perf Half Y2.12%
Book/sh14.48 P/B4.47 EPS next Y-5.35% ROA0.20% Target Price74.85 Perf Year-12.04%
Cash/sh5.89 P/C10.97 EPS next 5Y3.26% ROE0.60% 52W Range56.56 - 85.79 Perf YTD10.99%
Dividend2.84 P/FCF19.98 EPS past 5Y-61.80% ROI5.00% 52W High-24.36% Beta0.41
Dividend %4.39% Quick Ratio1.30 Sales past 5Y-5.40% Gross Margin81.50% 52W Low14.73% ATR1.32
Employees13600 Current Ratio1.40 Sales Q/Q26.20% Oper. Margin16.50% RSI (14)50.12 Volatility1.55% 1.86%
OptionableYes Debt/Eq1.73 EPS Q/Q-42.80% Profit Margin0.50% Rel Volume0.74 Prev Close64.66
ShortableYes LT Debt/Eq1.57 EarningsFeb 04 AMC Payout- Avg Volume8.23M Price64.89
Recom2.30 SMA20-0.12% SMA500.16% SMA200-0.13% Volume6,122,263 Change0.36%
Apr-01-21Upgrade Bernstein Mkt Perform → Outperform $80
Mar-30-21Upgrade Redburn Neutral → Buy
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $83
Jan-04-21Upgrade Guggenheim Neutral → Buy
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
Oct-28-20Initiated UBS Neutral $61
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-13-21 02:09PM  
10:51AM  
09:28AM  
Apr-12-21 01:51PM  
Apr-09-21 01:39PM  
Apr-08-21 04:20PM  
03:23PM  
01:23PM  
09:34AM  
08:14AM  
06:55AM  
06:47AM  
Apr-07-21 07:53PM  
04:34PM  
03:13PM  
01:26PM  
11:01AM  
Apr-06-21 01:29PM  
01:01AM  
Apr-05-21 02:06PM  
07:13AM  
Apr-02-21 06:09AM  
Apr-01-21 04:15PM  
02:45PM  
01:46PM  
Mar-31-21 01:42PM  
09:55AM  
12:26AM  
Mar-30-21 01:27PM  
10:44AM  
Mar-29-21 09:15AM  
Mar-26-21 05:50PM  
02:14PM  
08:48AM  
08:30AM  
07:38AM  
07:28AM  
Mar-25-21 04:01PM  
06:15AM  
Mar-24-21 02:56PM  
01:34PM  
10:46AM  
Mar-23-21 09:09PM  
10:20AM  
09:41AM  
Mar-22-21 01:49PM  
09:28AM  
09:25AM  
03:23AM  
Mar-20-21 07:37PM  
Mar-19-21 10:06AM  
Mar-18-21 05:50PM  
02:04PM  
10:30AM  
05:00AM  
Mar-17-21 02:00PM  
01:35PM  
10:30AM  
06:04AM  
Mar-16-21 02:43PM  
02:09PM  
01:30PM  
11:23AM  
10:26AM  
Mar-15-21 04:29PM  
02:04PM  
01:05PM  
10:46AM  
10:19AM  
09:38AM  
08:08AM  
06:45AM  
06:43AM  
Mar-14-21 07:38AM  
Mar-12-21 03:11PM  
01:57PM  
01:40PM  
12:23PM  
09:43AM  
09:39AM  
Mar-11-21 02:44PM  
02:10PM  
01:57PM  
01:32PM  
12:00PM  
09:28AM  
02:39AM  
Mar-10-21 03:14PM  
03:08PM  
02:14PM  
01:57PM  
01:44PM  
11:13AM  
10:20AM  
09:55AM  
Mar-09-21 01:37PM  
01:22PM  
Mar-08-21 05:45PM  
02:28PM  
02:03PM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 11Sale63.361,48694,15329,166Mar 12 06:39 PM
Wilfong Diane E.SVP, Controller & CAOFeb 10Option Exercise0.00778017,606Feb 11 05:58 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale67.411,975133,13528,832Feb 11 05:56 PM
Wilfong Diane E.SVP, Controller & CAOFeb 06Option Exercise0.001,866017,361Feb 09 07:46 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise0.002,728031,560Feb 09 07:44 PM
Dickinson Andrew DEVP, Chief Financial OfficerFeb 06Option Exercise0.001,818033,081Feb 09 07:41 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 01Sale65.979,711640,63328,832Feb 03 06:23 PM
Lofton Kevin EDirectorJan 22Option Exercise20.6420,282418,72274,203Jan 25 01:55 PM
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM